Construction/NN
of/IN
Deletion/NN
Map/NN
of/IN
16q/NN
by/IN
LOH/NN
Analysis/NN
from/IN
HCC/NN
Patients/NNS
and/CC
Physical/JJ
Map/NN
on/IN
16q/NN
23.3/CD
-/:
24.1/CD
Region/NN
./.
====================
Loss/NN
of/IN
heterozygosity/NN
(/(
LOH/NN
)/)
has/VBZ
been/VBN
used/VBN
to/TO
detect/VB
====================
deleted/VBN
regions/NNS
of/IN
a/DT
specific/JJ
chromosome/NN
in/IN
cancer/NN
cells/NNS
./.
====================
LOH/NN
on/IN
chromosome/NN
16q/NN
has/VBZ
been/VBN
reported/VBN
to/TO
occur/VB
frequently/RB
in/IN
progressed/VBN
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
./.
====================
Liver/RB
tissues/NNS
from/IN
37/CD
Korean/NN
HCC/NN
patients/NNS
were/VBD
analyzed/VBN
for/IN
LOH/NN
by/IN
using/VBG
25/CD
polymorphic/JJ
microsatellite/NN
markers/NNS
distributed/VBN
along/IN
16q/NN
./.
====================
Out/CC
of/IN
the/DT
37/CD
HCC/NN
patients/NNS
studied/VBD
,/,
21/CD
patients/NNS
(/(
56.8/CD
%/NN
)/)
showed/VBD
LOH/NN
in/IN
various/JJ
regions/NNS
of/IN
16q/NN
with/IN
at/IN
least/JJS
one/CD
polymorphic/JJ
marker/NN
./.
====================
Puring/VBG
the/DT
analysis/NN
of/IN
these/DT
21/CD
LOH/NN
cases/NNS
,/,
6/CD
patients/NNS
showed/VBD
interstitial/JJ
LOHs/NNS
in/IN
which/WDT
the/DT
boundary/NN
of/IN
the/DT
LOH/NN
region/NN
was/VBD
defined/VBN
./.
====================
With/IN
two/CD
rounds/NNS
of/IN
LOH/NN
analysis/NN
,/,
five/CD
commonly/RB
occurring/VBG
interstitial/JJ
LOH/NN
regions/NNS
were/VBD
identified/VBN
;/:
16q21-22.1,16q22.2/CD
-/:
22.3/CD
,/,
16q22.3/CD
,/,
16q23.2/CD
and/CC
16q23.3/NN
-/:
24.1/CD
./.
====================
Among/IN
the/DT
five/CD
LOH/NN
regions/NNS
the/DT
16q23.3/NN
-/:
24.1/CD
region/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
related/JJ
with/IN
chromosome/NN
instability/NN
./.
====================
A/DT
complete/JJ
physical/JJ
map/NN
,/,
which/WDT
covers/VBZ
the/DT
3.2/CD
Mb/NN
region/NN
of/IN
16q23.3/NN
-/:
24.1/CD
(/(
D16S402/NN
and/CC
D16S486/NN
)/)
,/,
was/VBD
constructed/VBN
to/TO
identify/VB
novel/JJ
candidate/NN
tumor/NN
suppressor/NN
genes/NNS
./.
====================
We/PRP
provide/VBP
the/DT
minimally/RB
tiling/VBG
path/NN
map/VBP
consisting/VBG
of/IN
28/CD
BAC/NN
clones/NNS
./.
====================
There/EX
was/VBD
one/CD
gap/NN
between/IN
NT_10422.11/NN
and/CC
NT_019609.9/CD
of/IN
the/DT
human/JJ
genome/NN
sequence/NN
contig/NN
(/(
NCBI/NN
sequence/NN
build/JJ
33/CD
,/,
April/NN
29/CD
,/,
2003/CD
)/)
./.
====================
This/DT
gap/NN
can/MD
be/VB
filled/VBN
by/IN
sequencing/NN
the/DT
R-1425M20/NN
clone/NN
which/WDT
bridges/VBZ
these/DT
sequence/NN
contigs/NNS
./.
====================
Hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
most/JJS
prevalent/JJ
cancers/NNS
,/,
including/VBG
stomach/NN
and/CC
lung/NN
cancer/NN
,/,
in/IN
Korea/NN
(/(
National/JJ
Statistical/JJ
Office/NNS
,/,
2001/CD
)/)
./.
====================
Aflatoxin/NN
B1/NN
,/,
chronic/JJ
infection/NN
of/IN
hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
and/CC
hepatitis/NN
C/NN
virus/NN
(/(
HCV/NN
)/)
are/VBP
known/VBN
as/IN
major/JJ
risk/NN
factors/NNS
for/IN
HCC/NN
(/(
Bradley/NNP
,/,
1999/CD
)/)
./.
====================
However/RB
,/,
the/DT
molecular/JJ
mechanism/NN
of/IN
liver/NN
cell/NN
transformation/NN
has/VBZ
not/RB
been/VBN
determined/VBN
yet/RB
./.
====================
The/DT
development/NN
of/IN
HCC/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
a/DT
multistep/JJ
process/NN
(/(
Sugimura/NN
,/,
1992/CD
)/)
./.
====================
Inactivation/NN
of/IN
tumor/NN
suppressor/NN
gene/NN
and/CC
activation/NN
of/IN
oncogene/NN
caused/VBD
by/IN
intragenic/JJ
mutations/NNS
or/CC
by/IN
deletions/NNS
can/MD
lead/VB
a/DT
cell/NN
to/TO
a/DT
transformed/VBN
state/NN
./.
====================
Several/JJ
genomic/JJ
regions/NNS
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
involved/VBN
in/IN
liver/NN
carcinogenesis/NN
./.
====================
These/DT
regions/NNS
are/VBP
mostly/RB
located/JJ
on/IN
chromosome/NN
arms/NNS
1/CD
p/NN
,/,
4q/NNP
,/,
5q/NNP
,/,
6q/JJ
,/,
8p/JJ
,/,
9p/RB
,/,
11/CD
p/NN
,/,
13q/NN
,/,
16q/RB
and/CC
17p/NN
,/,
indicating/VBG
that/IN
dysfunctions/NNS
of/IN
diverse/JJ
tumor/NN
or/CC
metastasis/NN
suppressor/NN
genes/NNS
located/JJ
on/IN
these/DT
chromosomes/NNS
are/VBP
involved/VBN
in/IN
the/DT
development/NN
of/IN
HCC/NN
(/(
Boige/NNP
et/FW
al./FW
,/,
1997/CD
;/:
Nagai/NNP
et/FW
al./FW
,/,
1997/CD
)/)
./.
====================
The/DT
studies/NNS
on/IN
loss/NN
of/IN
heterozygosity/NN
(/(
LOH/NN
)/)
have/VBP
been/VBN
used/VBN
for/IN
detection/NN
of/IN
chromosomal/JJ
regions/NNS
deleted/VBN
in/IN
various/JJ
types/NNS
of/IN
cancer/NN
./.
====================
By/IN
analyzing/VBG
deleted/VBN
genes/NNS
in/IN
cancer/NN
patients/NNS
,/,
tumor/NN
suppressor/NN
genes/NNS
,/,
such/JJ
as/IN
BRCA2/NN
and/CC
DPC4/NN
,/,
were/VBD
identified/VBN
(/(
Hahn/NN
et/FW
al./FW
,/,
1995/CD
;/:
Wooster/NNP
et/FW
al./FW
,/,
1995/CD
)/)
./.
====================
Therefore/RB
,/,
detecting/VBG
the/DT
regions/NNS
associated/VBN
with/IN
high/JJ
LOH/NN
frequency/NN
is/VBZ
important/JJ
for/IN
identifying/VBG
negatively/RB
regulating/VBG
genes/NNS
participating/VBG
in/IN
tumor/NN
growth/NN
,/,
such/JJ
as/IN
tumor/NN
suppressor/NN
genes/NNS
(/(
TSGs/NNS
)/)
./.
====================
High/JJ
frequency/NN
of/IN
LOH/NN
has/VBZ
been/VBN
observed/VBN
on/IN
human/JJ
chromosome/NN
16q/NN
in/IN
HCC/NN
,/,
as/IN
well/RB
as/IN
in/IN
other/JJ
cancers/NNS
including/VBG
breast/NN
cancer/NN
(/(
Cleton-/NN
Jansen/NN
et/FW
al./FW
,/,
1999/CD
)/)
,/,
prostate/NN
cancer/NN
(/(
Carter/NN
et/FW
al./FW
,/,
1990/CD
)/)
./.
====================
and/CC
Wilm/JJ
's/POS
tumor/NN
(/(
Maw/NN
etal./FW
,/,
1992/CD
)/)
,/,
indicating/VBG
that/IN
one/CD
or/CC
more/RBR
TSGs/NNS
may/MD
exist/VB
on/IN
16q/NN
./.
====================
It/PRP
would/MD
be/VB
useful/JJ
to/TO
define/VB
commonly/RB
and/CC
minimally/RB
deleted/VBN
regions/NNS
on/IN
a/DT
specific/JJ
chromosomal/JJ
region/NN
of/IN
patients/NNS
to/TO
search/VB
the/DT
possible/JJ
TSGs/NNS
./.
====================
Even/RB
after/IN
the/DT
completion/NN
of/IN
the/DT
human/JJ
genome/NN
project/VB
,/,
there/EX
are/VBP
still/RB
a/DT
considerable/JJ
amount/NN
of/IN
gaps/NNS
between/IN
certain/JJ
sequence/NN
contigs/NNS
./.
====================
BAC/NN
contig/NN
maps/VBZ
of/IN
human/JJ
chromosomes/NNS
are/VBP
still/RB
a/DT
valuable/JJ
resource/NN
for/IN
positional/JJ
cloning/VBG
of/IN
the/DT
genes/NNS
associated/VBN
with/IN
diseases/NNS
and/CC
,/,
in/IN
particular/JJ
,/,
for/IN
sequencing/NN
of/IN
the/DT
gaps/NNS
present/JJ
on/IN
the/DT
human/JJ
genome/NN
draft/NN
sequences/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
report/VBP
five/CD
commonly/RB
occurring/VBG
LOH/NN
regions/NNS
on/IN
human/JJ
16q/NN
from/IN
Korean/JJ
HCC/NN
patients/NNS
and/CC
a/DT
BAC/NN
contig/NN
map/VBP
for/IN
one/CD
of/IN
the/DT
LOH/NN
regions/NNS
with/IN
complete/JJ
====================
coverage/NN
./.
====================
Single/JJ
gap/NN
present/JJ
in/IN
the/DT
human/JJ
draft/NN
sequences/NNS
in/IN
this/DT
region/NN
is/VBZ
closed/VBN
with/IN
our/PRP$
BAC/NN
contig/NN
sequence/NN
./.
====================
HCC/NN
and/CC
non-tumorous/JJ
tissues/NNS
were/VBD
prepared/VBN
from/IN
37/CD
patients/NNS
who/WP
had/VBD
undergone/NN
hepatectomy/NN
at/IN
the/DT
Department/JJ
of/IN
Surgery/NN
,/,
Korea/NN
Cancer/NN
Center/NN
Hospital/JJ
./.
====================
Tumor/NN
and/CC
non-tumor/JJ
samples/NNS
were/VBD
kept/IN
frozen/VBN
at/IN
-70°c/JJ
after/IN
removed/VBN
from/IN
patients/NNS
until/IN
DNA/NN
extraction/NN
./.
====================
Differentiation/NN
states/NNS
of/IN
tumor/NN
samples/NNS
were/VBD
ranged/VBN
from/IN
stages/NNS
1/CD
to/TO
4/CD
./.
====================
There/EX
were/VBD
32/CD
cases/NNS
positive/JJ
for/IN
HBV/NN
./.
====================
Average/NN
tumor/NN
size/NN
was/VBD
6.2/CD
cm/NN
./.
====================
The/DT
age/NN
of/IN
patients/NNS
was/VBD
ranged/VBN
from/IN
24/CD
to/TO
67/CD
./.
====================
The/DT
sequences/NNS
of/IN
dinucleotide/NN
polymorphic/JJ
markers/NNS
were/VBD
obtained/VBN
by/IN
searching/VBG
the/DT
Genome/NN
Database/NN
(/(
GDB/NN
:/:
http/NN
:/:
//www.gdb.org/JJ
)/)
and/CC
from/IN
a/DT
previous/JJ
report/NN
(/(
Dogget/NN
et/FW
al./FW
,/,
1995/CD
)/)
./.
====================
The/DT
sequences/NNS
of/IN
tetranucleotide/NN
repeat/NN
markers/NNS
and/CC
somatic/JJ
cell/NN
hybrid/NN
panels/NNS
were/VBD
kindly/RB
provided/VBD
by/IN
Dr./NNP
Callen/FW
(/(
Women/NNP
’/CD
s/NNS
and/CC
Children/NN
’/CD
s/NNS
Hospital/JJ
,/,
Adelaide/NN
,/,
Australia/NN
)/)
./.
====================
Polymorphic/JJ
markers/NNS
retaining/VBG
high/JJ
heterozygosity/NN
score/RB
more/RBR
than/IN
0.7/CD
were/VBD
selected/VBN
,/,
except/IN
two/CD
markers/NNS
(/(
D16S416/NN
and/CC
D16S518/NN
)/)
./.
====================
Genomic/JJ
DNA/NN
was/VBD
prepared/VBN
from/IN
the/DT
tissues/NNS
as/IN
described/VBN
by/IN
Sambrook/NN
et/FW
al/JJ
./.
====================
(/(
2001/CD
)/)
./.
====================
PCR/NN
was/VBD
performed/VBN
under/IN
a/DT
standard/JJ
condition/NN
(/(
Yeh/NN
et/FW
al./FW
,/,
1996/CD
)/)
./.
====================
The/DT
PCR/NN
products/NNS
were/VBD
labeled/VBN
with/IN
a-/NN
[/(
32/CD
P/NN
]/)
-dCTP/NN
./.
====================
Amplified/VBN
DNAs/NNS
were/VBD
subjected/VBN
to/TO
6/CD
%/NN
polyacrylamide/NN
gel/NN
electrophoresis/NN
./.
====================
The/DT
gel/NN
was/VBD
dried/VBN
and/CC
processed/VBN
for/IN
autoradiography/NN
./.
====================
Allelic/JJ
loss/NN
was/VBD
scored/VBN
when/WRB
band/NN
intensity/NN
of/IN
one/CD
allelic/JJ
marker/NN
was/VBD
significantly/RB
decreased/VBD
(/(
more/RBR
than/IN
50/CD
%/NN
)/)
in/IN
tumor/NN
DNA/NN
compared/VBN
to/TO
that/DT
in/IN
normal/JJ
DNA/NN
./.
====================
Initial/JJ
screening/NN
of/IN
high/JJ
density/NN
membrane/NN
====================
High/JJ
density/NN
filters/NNS
of/IN
human/JJ
D1/D2/NN
were/VBD
prepared/VBN
by/IN
====================
using/VBG
Q-Bot/JJ
(/(
Genetiks/NNS
)/)
and/CC
RPCI-11/NN
library/NN
was/VBD
purchased/VBN
from/IN
Children/NN
’/CD
s/NNS
Hospital/JJ
Okland/CC
Research/NN
Institute/JJ
./.
====================
Probes/NNS
were/VBD
prepared/VBN
by/IN
amplifying/VBG
gDNA/NN
with/IN
PCR/NN
and/CC
by/IN
labeling/VBG
with/IN
a-/NN
[/(
32/CD
P/NN
]/)
-dCTP/NN
./.
====================
Ten/CD
to/TO
twenty/JJ
probes/NNS
were/VBD
pooled/JJ
and/CC
hybridized/VBD
to/TO
each/DT
high/JJ
density/NN
filter/NN
./.
====================
True/JJ
positive/JJ
clones/NNS
were/VBD
selected/VBN
and/CC
then/RB
subjected/VBD
to/TO
deconvolution/NN
experiments/NNS
to/TO
identify/VB
clones/NNS
specific/JJ
to/TO
individual/JJ
probes/NNS
(/(
Cao/NN
etal./FW
,/,
1999/CD
)/)
./.
====================
Each/DT
clone/NN
was/VBD
digested/VBN
with/IN
restriction/NN
enzyme/NN
,/,
labeled/VBN
====================
with/IN
a-/JJ
[/(
32/CD
P/NN
]/)
-dATP/NN
and/CC
AMV-RT/NN
,/,
subjected/VBN
to/TO
poly­/JJ
acrylamide/IN
gel/NN
electrophoresis/NN
,/,
processed/VBN
for/IN
autora­/JJ
diography/NN
and/CC
the/DT
image/NN
was/VBD
then/RB
analyzed/VBD
with/IN
the/DT
FPC/NN
2.5/CD
software/RB
(/(
see/VB
Cao/NN
et/FW
al./FW
,/,
1998/CD
for/IN
detailed/JJ
procedure/NN
)/)
./.
====================
Nine/NN
contigs/NNS
were/VBD
initially/RB
obtained/VBN
./.
====================
Gaps/RB
were/VBD
filled/VBN
by/IN
chromosome/NN
walking/NN
./.
====================
Briefly/RB
,/,
probes/NNS
were/VBD
prepared/VBN
from/IN
BAC/NN
end/NN
sequences/NNS
of/IN
each/DT
contig/NN
which/WDT
were/VBD
used/VBN
to/TO
screen/VB
high/JJ
density/NN
membranes/NNS
./.
====================
End/CC
sequences/NNS
of/IN
each/DT
positive/JJ
BAC/NN
clone/NN
were/VBD
determined/VBN
and/CC
PCR/NN
primers/NNS
were/VBD
designed/VBN
from/IN
the/DT
BAC/NN
end/NN
sequences/NNS
./.
====================
All/DT
positive/JJ
BAC/NN
clones/NNS
obtained/VBN
from/IN
each/DT
screening/NN
were/VBD
used/VBN
as/IN
PCR/NN
templates/NNS
./.
====================
The/DT
generation/NN
of/IN
PCR/NN
product/NN
was/VBD
used/VBN
as/IN
criteria/NNS
for/IN
determining/VBG
overlap/IN
./.
====================
The/DT
end/NN
sequences/NNS
of/IN
outermost/JJ
BAC/NN
clones/NNS
were/VBD
used/VBN
to/TO
prepare/VB
new/JJ
probes/NNS
for/IN
the/DT
second/JJ
round/NN
screening/NN
./.
====================
Chromosome/NN
walking/VBG
was/VBD
continued/VBN
until/IN
gaps/VBZ
were/VBD
closed/VBN
./.
====================
Gap/NN
closing/VBG
was/VBD
also/RB
determined/VBN
by/IN
PCR/NN
./.
====================
Forty/CD
polymorphic/JJ
markers/NNS
with/IN
high/JJ
heterozygosity/NN
score/RB
(/(
higher/JJR
than/IN
0.70/CD
according/VBG
to/TO
GDB/NN
)/)
were/VBD
initially/RB
selected/VBN
./.
====================
Some/DT
markers/NNS
,/,
however/RB
,/,
having/VBG
lower/JJR
heterozygosity/NN
score/RB
than/IN
0.7/CD
were/VBD
selected/VBN
to/TO
keep/VB
marker/NN
intervals/NNS
approximately/RB
3/CD
Mb/NN
./.
====================
The/DT
markers/NNS
consist/VBP
of/IN
thirty/NN
one/CD
dinucleotide/NN
and/CC
nine/CD
tetranucleotide/NN
repeat/NN
polymorphic/JJ
markers/NNS
./.
====================
To/TO
validate/VB
these/DT
markers/NNS
,/,
selected/VBN
markers/NNS
were/VBD
subjected/VBN
to/TO
PCR-based/JJ
analysis/NN
./.
====================
As/IN
a/DT
result/NN
,/,
21/CD
dinucleotide/NN
polymorphic/JJ
markers/NNS
and/CC
4/CD
tetranucleotide/NN
repeat/NN
markers/NNS
were/VBD
finally/RB
selected/VBN
to/TO
be/VB
useful/JJ
for/IN
LOH/NN
analysis/NN
on/IN
HCC/NN
cases/NNS
./.
====================
The/DT
heterozygosity/NN
scores/VBZ
of/IN
each/DT
marker/NN
in/IN
the/DT
GDB/NN
database/NN
were/VBD
compared/VBN
to/TO
those/DT
obtained/VBN
from/IN
the/DT
LOH/NN
study/NN
of/IN
Korean/JJ
HCC/NN
cases/NNS
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
some/DT
markers/NNS
showed/VBD
higher/JJR
dissimilarity/NN
in/IN
heterozygosity/NN
score/RB
in/IN
Korean/JJ
population/NN
compared/VBN
to/TO
those/DT
in/IN
the/DT
database/NN
(/(
see/VB
Table/JJ
1/CD
)/)
./.
====================
This/DT
discrepancy/NN
in/IN
marker/NN
informativeness/VBP
may/MD
be/VB
due/JJ
to/TO
ethnic/JJ
difference/NN
(/(
Uthoff/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Although/IN
heterozygosity/NN
score/RB
information/NN
of/IN
tetranucleotide/NN
repeat/NN
markers/NNS
could/MD
not/RB
be/VB
obtained/VBN
from/IN
GDB/NN
database/NN
,/,
we/PRP
====================
chose/NN
them/PRP
because/IN
of/IN
marker/NN
intervals/NNS
./.
====================
The/DT
heterozygosity/NN
scores/VBZ
of/IN
the/DT
tetranucleotide/NN
polymorphic/JJ
markers/NNS
ranged/VBD
from/IN
0.4/CD
to/TO
0.71/CD
in/IN
37/CD
Koreans/NNS
./.
====================
Tetranucleotide/NN
repeat/NN
markers/NNS
showed/VBD
single/JJ
specific/JJ
bands/NNS
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
dinucleotide/NN
repeat/NN
markers/NNS
showed/VBD
multiple/JJ
bands/NNS
ranging/VBG
from/IN
4/CD
to/TO
6/CD
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Multiple/JJ
bands/NNS
from/IN
dinucleotide/NN
repeat/NN
markers/NNS
might/MD
be/VB
occurred/VBN
due/IN
to/TO
polymerase/NN
slippage/JJ
./.
====================
LOH/NN
mapping/NN
was/VBD
carried/VBN
out/RP
in/IN
two/CD
steps/NNS
in/IN
this/DT
study/NN
./.
====================
Overall/RB
LOH/NN
profile/NN
on/IN
16q/NN
was/VBD
examined/VBN
in/IN
the/DT
first/JJ
step/NN
./.
====================
Markers/NNS
that/DT
have/VBP
long/JJ
intervals/NNS
(/(
3/CD
Mb/NN
in/IN
average/JJ
)/)
were/VBD
chosen/NN
for/IN
the/DT
first/JJ
step/NN
LOH/NN
analysis/NN
,/,
and/CC
the/DT
rough/JJ
LOH/NN
regions/NNS
were/VBD
determined/VBN
./.
====================
In/IN
the/DT
second/JJ
step/NN
,/,
additional/JJ
markers/NNS
were/VBD
used/VBN
to/TO
reduce/VB
the/DT
length/NN
of/IN
each/DT
LOH/NN
region/NN
./.
====================
Eighteen/CD
markers/NNS
,/,
showing/VBG
3/CD
Mb/NN
of/IN
interval/JJ
size/NN
in/IN
average/JJ
,/,
were/VBD
used/VBN
in/IN
the/DT
first/JJ
step/NN
of/IN
LOH/NN
analysis/NN
./.
====================
Twenty/CD
one/CD
out/RB
of/IN
37/CD
HCC/NN
patients/NNS
showed/VBD
LOH/NN
with/IN
at/IN
least/JJS
one/CD
polymorphic/JJ
marker/NN
,/,
however/RB
,/,
16/CD
patients/NNS
showed/VBD
no/DT
LOH/NN
at/IN
all/DT
./.
====================
Fifteen/CD
out/IN
of/IN
the/DT
21/CD
LOH-showing/JJ
patients/NNS
were/VBD
observed/VBN
to/TO
have/VB
extensive/JJ
deletions/NNS
throughout/IN
the/DT
entire/JJ
long/JJ
arm/NN
of/IN
chromosome/NN
16/CD
,/,
while/IN
the/DT
other/JJ
six/CD
patients/NNS
showed/VBD
interstitial/JJ
LOHs/NNS
on/IN
the/DT
16q/NN
./.
====================
The/DT
position/NN
of/IN
each/DT
marker/NN
was/VBD
determined/VBN
according/VBG
to/TO
the/DT
sequence/NN
contig/NN
of/IN
human/JJ
genomic/JJ
sequence/NN
database/NN
and/CC
Genethon/NN
linkage/NN
map/VBP
provided/VBD
by/IN
NCBI/NN
./.
====================
Four/CD
common/JJ
LOH/NN
regions/NNS
were/VBD
observed/VBN
in/IN
the/DT
first/JJ
step/NN
LOH/NN
analysis/NN
./.
====================
The/DT
first/JJ
region/NN
was/VBD
located/JJ
between/IN
D16S503/NN
and/CC
D16S512/NN
marker/NN
(/(
10.48/CD
Mb/NN
in/IN
length/NN
)/)
./.
====================
The/DT
second/JJ
region/NN
was/VBD
located/JJ
between/IN
D16S512/NN
and/CC
D16S3098/NN
(/(
7.38/CD
Mb/NN
)/)
./.
====================
The/DT
third/JJ
region/NN
was/VBD
located/JJ
between/IN
D16S505/NN
and/CC
D16S402/NN
(/(
1.62/CD
Mb/NN
)/)
./.
====================
The/DT
fourth/JJ
region/NN
was/VBD
located/JJ
between/IN
D16S402/NN
and/CC
D16S486/NN
(/(
3.2/CD
Mb/NN
)/)
./.
====================
To/TO
reduce/VB
the/DT
size/NN
of/IN
each/DT
LOH/NN
region/NN
,/,
we/PRP
further/RB
====================
performed/VBN
LOH/NN
analysis/NN
by/IN
using/VBG
7/CD
additional/JJ
polymorphic/JJ
markers/NNS
located/JJ
inside/RB
of/IN
each/DT
LOH/NN
region/NN
./.
====================
Four/CD
markers/NNS
(/(
D16S3019/NN
,/,
D16S397/NN
,/,
D16S496/NN
and/CC
D16S3066/NN
)/)
were/VBD
used/VBN
to/TO
reduce/VB
the/DT
length/NN
of/IN
the/DT
first/JJ
region/NN
./.
====================
Because/IN
D16S3019/NN
,/,
D16S397/NN
and/CC
D16S496/NN
showed/VBD
LOHs/NNS
or/CC
homozygosities/NNS
in/IN
the/DT
six/CD
interstitial/JJ
LOH/NN
cases/NNS
,/,
these/DT
markers/NNS
did/VBD
not/RB
contribute/VB
to/TO
reduce/VB
the/DT
length/NN
of/IN
the/DT
first/JJ
LOH/NN
region/NN
./.
====================
D16S3066/CD
was/VBD
located/JJ
inside/RB
of/IN
the/DT
first/JJ
LOH/NN
region/NN
and/CC
0.73/CD
Mb/NN
apart/VBP
from/IN
D16S516/NN
./.
====================
This/DT
marker/NN
did/VBD
not/RB
show/VB
LOH/NN
in/IN
two/CD
patients/NNS
./.
====================
The/DT
first/JJ
region/NN
,/,
therefore/RB
,/,
could/MD
be/VB
reduced/VBN
by/IN
0.37/CD
Mb/NN
./.
====================
D16S266/CD
,/,
D16S3090/NN
and/CC
D16S516/NN
markers/NNS
were/VBD
used/VBN
to/TO
reduce/VB
the/DT
second/JJ
LOH/NN
region/NN
./.
====================
D16S3090/CD
showed/VBD
retention/NN
of/IN
LOH/NN
./.
====================
Both/DT
D16S266/CD
and/CC
D16S516/NN
showed/VBD
no/DT
LOH/NN
in/IN
three/CD
cases/NNS
./.
====================
D16S266/CD
was/VBD
located/JJ
approximately/RB
in/IN
the/DT
middle/JJ
of/IN
the/DT
second/JJ
LOH/NN
region/NN
,/,
and/CC
the/DT
markers/NNS
neighboring/VBG
on/IN
both/CC
right/JJ
and/CC
left/NN
side/JJ
of/IN
D16S266/NN
showed/VBD
LOH/NN
./.
====================
Therefore/RB
,/,
the/DT
second/JJ
LOH/NN
region/NN
could/MD
be/VB
divided/VBN
into/IN
two/CD
LOH/NN
regions/NNS
(/(
LOH/NN
region/NN
2/CD
and/CC
3/CD
)/)
./.
====================
The/DT
location/NN
of/IN
D16S516/NN
was/VBD
2.63/CD
Mb/NN
apart/VBP
inside/NN
from/IN
D16S3098/NN
,/,
and/CC
it/PRP
showed/VBD
no/DT
LOH/NN
./.
====================
The/DT
length/NN
of/IN
LOH/NN
region/NN
3/CD
was/VBD
,/,
therefore/RB
,/,
reduced/VBD
to/TO
2.63/CD
Mb/NN
./.
====================
No/DT
additional/JJ
markers/NNS
were/VBD
found/VBN
in/IN
the/DT
third/JJ
and/CC
fourth/IN
LOH/NN
regions/NNS
in/IN
the/DT
first/JJ
step/NN
analysis/NN
./.
====================
The/DT
size/NN
of/IN
these/DT
regions/NNS
,/,
therefore/RB
,/,
could/MD
not/RB
be/VB
reduced/VBN
./.
====================
By/IN
combining/VBG
the/DT
first/JJ
and/CC
second/JJ
step/NN
of/IN
LOH/NN
analysis/NN
,/,
five/CD
LOH/NN
regions/NNS
were/VBD
obtained/VBN
./.
====================
Region/NN
1/CD
was/VBD
located/JJ
at/IN
16q21/CD
-22.1/CD
between/IN
markers/NNS
D16S503/NN
and/CC
D16S3066/NN
,/,
region,2/NN
at/IN
16q22.2/CD
-/:
22.3/CD
between/IN
D16S512/NN
and/CC
D16S266/NN
,/,
region/NN
3/CD
at/IN
16q22.3/CD
between/IN
D16S266/CD
and/CC
D16S516/NN
,/,
region/NN
4/CD
at/IN
16q23.2/CD
between/IN
D16S505/NN
and/CC
D16S402/NN
,/,
and/CC
region/NN
5/CD
at/IN
16q23.3/CD
-/:
24.1/CD
between/IN
====================
D16S402/NN
and/CC
D16S486/NN
./.
====================
The/DT
lengths/NNS
of/IN
LOH/NN
region/NN
1/CD
to/TO
5/CD
were/VBD
9.7/CD
,/,
2.6/CD
,/,
2.4,1.6/CD
and/CC
3.2/CD
Mb/NN
,/,
respectively/RB
./.
====================
The/DT
LOH/NN
analysis/NN
data/NNS
and/CC
position/NN
of/IN
markers/NNS
were/VBD
summarized/VBN
as/IN
an/DT
integrated/JJ
map/VBP
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
Relationship/NN
between/IN
the/DT
LOH/NN
occurrence/NN
and/CC
clinicopathological/JJ
parameters/NNS
was/VBD
analyzed/VBN
./.
====================
No/DT
significant/JJ
difference/NN
was/VBD
observed/VBN
in/IN
gender/NN
,/,
age/NN
and/CC
status/NN
of/IN
hepatitis/NN
viruses/NNS
between/IN
LOH/NN
patients/NNS
and/CC
non-/NN
LOH/NN
patients/NNS
./.
====================
Big/NN
difference/NN
was/VBD
,/,
however/RB
,/,
observed/VBN
in/IN
average/JJ
tumor/NN
size/NN
of/IN
LOH/NN
patients/NNS
compared/VBD
to/TO
those/DT
of/IN
non-LOH/JJ
patients/NNS
./.
====================
The/DT
average/JJ
size/NN
of/IN
tumor/NN
in/IN
LOH/NN
patients/NNS
was/VBD
approximately/RB
2/CD
cm/NN
larger/JJR
than/IN
those/DT
in/IN
non-/NN
LOH/NN
patients/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
The/DT
average/JJ
a-fetoprotein/NN
level/NN
of/IN
the/DT
patients/NNS
showing/VBG
LOH/NN
was/VBD
35.7/CD
/zg/ml/NN
./.
====================
This/DT
value/NN
is/VBZ
much/RB
higher/JJR
than/IN
that/DT
of/IN
the/DT
patients/NNS
showing/VBG
non-/NN
LOH/NN
(/(
488/CD
ng/ml/NN
in/IN
average/JJ
)/)
./.
====================
However/RB
,/,
there/EX
is/VBZ
still/RB
no/DT
evidence/NN
at/IN
the/DT
molecular/JJ
level/NN
to/TO
explain/VB
the/DT
significance/NN
of/IN
this/DT
relationship/NN
./.
====================
Our/PRP$
final/JJ
goal/NN
is/VBZ
to/TO
isolate/VB
novel/JJ
gene/NN
(/(
s/NNS
)/)
which/WDT
is/VBZ
(/(
are/VBP
)/)
====================
related/JJ
with/IN
HOC/NN
./.
====================
FRA16D/NN
,/,
located/JJ
in/IN
the/DT
region/NN
5/CD
,/,
was/VBD
reported/VBN
to/TO
be/VB
related/JJ
to/TO
chromosome/NN
instability/NN
(/(
Doggett/NN
et/FW
al/JJ
,/,
1995/CD
)/)
./.
====================
No/DT
TSGs/NNS
have/VBP
been/VBN
reported/VBN
yet/RB
in/IN
this/DT
region/NN
./.
====================
We/PRP
,/,
therefore/RB
,/,
decided/VBD
to/TO
generate/VB
a/DT
physical/JJ
map/NN
between/IN
D16S402/NN
and/CC
D15S486/NN
(/(
16q23.3/CD
-/:
16q24.1/CD
)/)
by/IN
using/VBG
BAC/NN
clones/NNS
./.
====================
Human/JJ
BAC/NN
library/NN
A/DT
was/VBD
screened/VBN
by/IN
a/DT
PCR-based/JJ
method/NN
as/IN
previously/RB
described/VBN
(/(
Kim/NN
et/FW
al./FW
,/,
1996/CD
)/)
./.
====================
Nine/NN
positive/JJ
BACs/NNS
were/VBD
obtained/VBN
by/IN
using/VBG
10/CD
STSs/NNS
,/,
the/DT
positions/NNS
of/IN
which/WDT
were/VBD
determined/VBN
with/IN
the/DT
previous/JJ
YAC-based/JJ
physical/JJ
map/NN
of/IN
chromosome/NN
16/CD
(/(
Doggett/NN
eta/./FW
,/,
1995/CD
)/)
./.
====================
The/DT
nine/CD
BACs/NNS
were/VBD
digested/VBN
with/IN
Not\/NN
enzyme/NN
,/,
subjected/VBN
to/TO
preparative/JJ
pulsed/JJ
field/NN
gel/NN
electrophoresis/NN
,/,
the/DT
inserts/NNS
isolated/VBN
from/IN
the/DT
gel/NN
and/CC
the/DT
isolated/VBN
inserts/NNS
used/VBN
as/IN
probes/NNS
for/IN
the/DT
screening/NN
of/IN
human/JJ
D1/NN
and/CC
D2/NN
library/NN
./.
====================
Seventy/NN
eight/CD
BACs/NNS
were/VBD
obtained/VBN
from/IN
high/JJ
density/NN
membrane/NN
screening/NN
./.
====================
The/DT
false/NN
positive/JJ
clones/NNS
were/VBD
removed/VBN
by/IN
Southern/NN
hybridization/NN
./.
====================
Thirteen/CD
and/CC
thirty/NN
one/CD
clones/NNS
were/VBD
identified/VBN
as/IN
real/JJ
positives/VBZ
from/IN
library/NN
D1/NN
and/CC
library/NN
D2/NN
,/,
respectively/RB
./.
====================
Six/CD
contigs/NNS
were/VBD
obtained/VBN
by/IN
fingerprinting/VBG
the/DT
positive/JJ
BACs/NNS
from/IN
A/DT
,/,
D1/NN
,/,
and/CC
D2/NN
library/NN
./.
====================
Chromosome/NN
walking/VBG
was/VBD
carried/VBN
out/RP
to/TO
fill/JJ
the/DT
gaps/NNS
located/JJ
among/IN
those/DT
six/CD
contigs/NNS
./.
====================
BACs/NNS
located/JJ
at/IN
the/DT
terminal/JJ
regions/NNS
of/IN
each/DT
contig/NN
were/VBD
subjected/VBN
to/TO
====================
sequencing/NN
./.
====================
BAC/NN
end/NN
sequences/NNS
were/VBD
used/VBN
to/TO
generate/VB
new/JJ
STS/NN
markers/NNS
./.
====================
D1/NN
and/CC
D2/NN
library/NN
screening/NN
was/VBD
carried/VBN
out/RP
with/IN
the/DT
probes/NNS
corresponding/VBG
to/TO
these/DT
BAC/NN
end/NN
sequence/NN
markers/NNS
./.
====================
By/IN
repeating/VBG
BAC/NN
end/NN
sequencing/NN
and/CC
chromosome/NN
walking/VBG
,/,
four/CD
gaps/NNS
were/VBD
filled/VBN
./.
====================
There/EX
was/VBD
still/RB
one/CD
gap/NN
left/NN
between/IN
the/DT
first/JJ
five/CD
contigs/NNS
and/CC
the/DT
sixth/NN
contig/NN
with/IN
D1/NN
and/CC
D2/NN
library/NN
,/,
but/CC
this/DT
gap/NN
was/VBD
filled/VBN
by/IN
the/DT
RPCI-11/NN
library/NN
screening/NN
./.
====================
By/IN
using/VBG
the/DT
end-sequenced/JJ
BACs/NNS
as/IN
starting/VBG
points/NNS
and/CC
also/RB
by/IN
adding/VBG
minimally/RB
overlapping/VBG
BACs/NNS
to/TO
each/DT
other/JJ
,/,
minimal/JJ
tiling/JJ
path/NN
was/VBD
constructed/VBN
,/,
spanning/VBG
between/IN
D16S402/NN
and/CC
D16S486/NN
in/IN
1.5X/CD
coverage/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Mega/DT
BLAST/NN
search/VBP
was/VBD
performed/VBN
to/TO
find/VB
the/DT
location/NN
of/IN
each/DT
STS/NNS
marker/NN
,/,
including/VBG
the/DT
BAC/NN
end/NN
sequences/NNS
,/,
on/IN
the/DT
human/JJ
genomic/JJ
sequence/NN
database/NN
in/IN
NCBI/NN
./.
====================
One/CD
gap/NN
existed/VBD
on/IN
the/DT
sequence/NN
contig/NN
of/IN
human/JJ
genome/NN
sequence/NN
at/IN
NCBI/NN
(/(
Sequence/NN
Build/JJ
33/CD
,/,
April/NN
29/CD
,/,
2003/CD
)/)
./.
====================
This/DT
gap/NN
was/VBD
bridged/VBN
by/IN
a/DT
R-1425M20/NN
clone/NN
./.
====================
We/PRP
identified/VBD
89/CD
STS/NNS
markers/NNS
and/CC
128/CD
BAC/NN
clones/NNS
in/IN
these/DT
regions/NNS
(/(
data/NNS
is/VBZ
available/JJ
upon/IN
request/VBP
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
constructed/VBD
a/DT
deletion/NN
map/VBP
of/IN
16q/NN
by/IN
====================
using/VBG
LOH/NN
analysis/NN
and/CC
constructing/VBG
a/DT
physical/JJ
map/NN
on/IN
one/CD
of/IN
the/DT
LOH/NN
regions/NNS
./.
====================
It/PRP
is/VBZ
important/JJ
to/TO
define/VB
the/DT
commonly/RB
deleted/VBN
region/NN
in/IN
human/JJ
cancers/NNS
to/TO
isolate/VB
gene/NN
(/(
s/NNS
)/)
related/JJ
to/TO
growth/NN
inhibition/NN
./.
====================
Five/CD
interstitial/JJ
LOH/NN
regions/NNS
were/VBD
located/JJ
on/IN
16q/NN
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
the/DT
LOH/NN
region/NN
1/CD
contains/VBZ
genes/NNS
related/JJ
to/TO
metastasis/NN
of/IN
cancer/NN
cell/NN
(/(
Nam/NN
etal./FW
,/,
2002/CD
)/)
./.
====================
Interestingly/RB
,/,
16q/NN
contains/VBZ
8/CD
cadherin/NN
gene/NN
clusters/NNS
./.
====================
Among/IN
these/DT
,/,
E-cadherin/NN
,/,
cadherin/NN
11/CD
,/,
cadherin/NN
16/CD
,/,
cadherin/NN
3/CD
and/CC
cadherin/NN
5/CD
are/VBP
located/JJ
on/IN
LOH/NN
region/NN
1/CD
./.
====================
It/PRP
is/VBZ
possible/JJ
that/IN
the/DT
LOH/NN
region/NN
1/CD
is/VBZ
broader/JJR
than/IN
the/DT
other/JJ
LOH/NN
regions/NNS
because/IN
the/DT
cadherin/NN
gene/NN
cluster/NN
is/VBZ
widely/RB
spread/VBN
throughout/IN
the/DT
entire/JJ
region/NN
1/CD
./.
====================
D16S515/NN
marker/NN
in/IN
LOH/NN
region/NN
2/CD
was/VBD
reported/VBN
to/TO
show/VB
23.3/CD
%/NN
of/IN
LOH/NN
frequency/NN
in/IN
Taiwanese/JJ
(/(
Chou/NNP
etal./FW
,/,
1998/CD
)/)
./.
====================
However/RB
,/,
this/DT
marker/NN
showed/VBD
65.5/CD
%/NN
of/IN
LOH/NN
frequency/NN
in/IN
Koreans/NNS
./.
====================
This/DT
difference/NN
in/IN
LOH/NN
frequency/NN
was/VBD
possibly/RB
originated/VBN
from/IN
the/DT
cause/NN
of/IN
HCC/NN
development/NN
or/CC
treatment/NN
of/IN
HCC/NN
patients/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
LOH/NN
was/VBD
frequently/RB
observed/VBN
in/IN
the/DT
LOH/NN
region/NN
3/CD
from/IN
HCC/NN
patients/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
CTRB/NN
locus/NN
inside/NN
of/IN
the/DT
LOH/NN
region/NN
3/CD
was/VBD
also/RB
reported/VBD
to/TO
be/VB
a/DT
commonly/RB
deleted/VBN
region/NN
in/IN
HCC/NN
(/(
Tsuda/NN
et/FW
al./FW
,/,
1990/CD
;/:
Yakicier/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
Chromosome/NN
16q23.1-24.1/CD
,/,
including/VBG
the/DT
LOH/NN
regions/NNS
4/CD
and/CC
5/CD
,/,
was/VBD
====================
reported/VBN
to/TO
be/VB
a/DT
consistently/RB
deleted/VBN
region/NN
among/IN
the/DT
patients/NNS
analyzed/VBD
by/IN
using/VBG
comparative/JJ
genomic/JJ
hybridization/NN
(/(
CGH/NN
)/)
studies/NNS
in/IN
HCC/NN
(/(
Balsara/NN
etal./FW
,/,
2001/CD
)/)
./.
====================
High/JJ
frequency/NN
of/IN
LOH/NN
in/IN
this/DT
CGH/NN
region/NN
from/IN
breast/NN
and/CC
prostate/NN
cancer/NN
was/VBD
reported/VBN
(/(
Gunnarsson/NN
et/FW
al./FW
,/,
2000/CD
;/:
Matsuyama/NNP
etal./FW
,/,
2003/CD
)/)
./.
====================
Although/IN
the/DT
human/JJ
genome/NN
sequencing/NN
was/VBD
announced/VBN
to/TO
be/VB
finished/VBN
,/,
there/EX
are/VBP
still/RB
many/JJ
sequence­/NN
gaps/VBZ
in/IN
the/DT
human/JJ
genome/NN
sequence/NN
./.
====================
We/PRP
found/VBD
one/CD
sequence-gap/NN
in/IN
LOH/NN
region/NN
5/CD
located/JJ
at/IN
16q23.3/CD
-/:
24.1/CD
./.
====================
Based/VBN
on/IN
complete/JJ
physical/JJ
map/NN
,/,
gap/NN
between/IN
NT.10422.11/NN
and/CC
NT_019609.9/CD
was/VBD
bridged/VBN
by/IN
the/DT
R-/NN
1425M20/CD
BAC/NN
clone/NN
./.
====================
Sequencing/NN
of/IN
R-1425M20/NN
could/MD
fill/RB
the/DT
gap/NN
between/IN
those/DT
sequence/NN
contigs/NNS
./.
====================
Thirty-three/DT
genes/NNS
were/VBD
predicted/VBN
to/TO
be/VB
located/JJ
in/IN
LOH/NN
region/NN
5/CD
according/VBG
to/TO
the/DT
NCBI/NN
map/VBP
viewer/JJR
(/(
Build/JJ
34/CD
Version/NN
1/CD
)/)
./.
====================
Among/IN
these/DT
,/,
one/CD
down/RB
regulated/VBN
gene/NN
(/(
OKL38/NN
)/)
in/IN
liver/NN
cancer/NN
was/VBD
identified/VBN
by/IN
the/DT
virtual/JJ
northern/NN
provided/VBD
by/IN
National/JJ
Cancer/NN
Institute/JJ
’/CD
s/NNS
Cancer/NN
Genome/NN
Anatomy/NN
Project/JJ
(/(
http/NN
:/:
//cgap.nci.nih.gov/LS
)/)
./.
====================
The/DT
ratio/NN
of/IN
OKL38/NN
expression/NN
level/NN
in/IN
HCC/NN
to/TO
normal/JJ
liver/NN
was/VBD
0/6/CD
./.
====================
We/PRP
are/VBP
currently/RB
examining/VBG
the/DT
expression/NN
level/NN
of/IN
the/DT
OKL38/NN
gene/NN
in/IN
HCC/NN
patients/NNS
./.
====================
Because/IN
LOH/NN
analysis/NN
does/VBZ
not/RB
give/VB
information/NN
if/IN
the/DT
LOH/NN
regions/NNS
are/VBP
located/JJ
in/IN
cis­/JJ
position/NN
or/CC
trans-position/NN
on/IN
sister/NN
chromatids/NNS
,/,
it/PRP
is/VBZ
necessary/JJ
to/TO
carry/VB
out/RP
haplotype/JJ
analysis/NN
to/TO
determine/VB
the/DT
phase/NN
of/IN
deletions/NNS
on/IN
chromosome/NN
./.
====================
